Soriot should explain the curious case of AstraZeneca’s non-dealPublished bytheguardian.comon •1 min readAstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholdersAstraZeneca falls to third-largest UK company amid US merger talksHold the heartburn pills.negóciosacquisiçãofarmacêuticoLearn moreShareLegalReport
